摘要
目的分析孟鲁司特联合氯雷他定治疗对咳嗽变异性哮喘(CVA)患儿肺功能的影响。方法选择2015-03~2016-09该院门诊收治的CVA患儿90例为研究对象,依入院顺序分为对照组和观察组,每组45例。两组患儿入院后均接受CVA常规治疗,对照组接受氯雷他定治疗,观察组在对照组基础上联合使用孟鲁司特治疗。对比两组患儿治疗前后肺功能指标、症状缓解时间及治疗效果。结果两组患儿治疗前呼气高峰流量(PEFR)、最大呼气量(FVE)、1 s用力呼气容积(FEV1)差异无统计学意义(P>0.05);治疗后两组患儿上述指标均较治疗前有所改善,且观察组均优于对照组(P<0.01)。观察组患儿咳嗽持续时间、哮喘持续时间、肺部哮鸣音消失时间均短于对照组,差异有统计学意义(P<0.01)。观察组显效23例,有效18例,无效4例;对照组显效14例,有效20例,无效11例,观察组疗效优于对照组(P<0.05)。结论孟鲁司特联合氯雷他定治疗对CVA患儿具有确切疗效。
Objective To analyze the effect of montelukast combined with loratadine on pulmonary function in children with cough variant asthma（ CVA）. Methods Ninety outpatients with CVA were collected as the research subjects in our hospital from March 2015 to September 2016. They were divided into the control group and the observation group according to the admission order,with 45 cases in each group. The two groups received routine treatment after admission. The control group received loratadine,and the observation group received montelukast in combination with loratatine. The lung function indexes,the symptoms and the curative effect were compared between the two groups before and after the treatment. Results There were no significant differences in the levels of PEFR,FVE and FEV1 between the two groups before the treatment（ P 0. 05）. After the treatment,the above indexes were improved more significantly in the observation group than those in the control group（ P 0. 01）. The duration of cough,asthma,lung wheezing disappear time in the observation group were significantly shorter than those in the control group（ P 0. 01）; In the observation group,23 cases were markedly effective,18 cases effective,and 4 cases invalid. In the control group,14 cases were markedly effective,20 cases effective,and 11 cases invalid. The curative effect of the observation group was better than that of the control group（ P 0. 05）. Conclusion Montelukast combined with loratadine is effective for the children with CVA.
出处
《中国临床新医学》
2017年第11期1077-1079,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
咳嗽变异性哮喘
孟鲁司特
氯雷他定
肺功能
Cough variant asthma（ CVA）
Montelukast
Loratadine
Pulmonary function
